POSTER SESSION V Wednesday, March 26, 2003   —  9:30 AM - 12:00 Noon EXHIBIT HALL A - C BREAST PATHOLOGY 1 The Favorable Prognostic Value of Estrogen Receptor Beta Immunohistochemical Expression in Invasive Breast Cancer (158) AC Lazaris, EG Panayotopoulou, NP Givalos, S Markaki, A Konstantinidou, A Keramopoulos, LL Nakopoulou Medical School, the National and Kapodistrian University of Athens, Athens, Greece 2 Expression of Estrogen Receptor Subunits (Alpha & Beta) and Progesterone Receptor Subunits (Alpha & Beta) in Breast Cancer (142) Q Ji, P Chen, P Liu, C Aoyama Olive View-UCLA Medical Center, Sylmar, CA 3 Expression of Androgen Receptor Coactivator 70 in Stage I and II Invasive Breast Cancer (160) P Lee, JS Liu, B Arun, T Smith, A Sahin The University of Texas, M. D. Anderson Cancer Center, Houston, TX 4 Androgen Receptors Are Frequently Expressed in Breast Carcinomas (172) F Moinfar, M Okcu, O Tsybrovskyy, P Regitnig, SF Lax, W Weybora, M Ratschek, FA Tavassoli, H Denk Graz, Austria; Washington, DC 5 Immunohistochemical (IMH) Demonstration of Androgen Receptor (AR) in Breast Cancer Using Tissue Microarray: Comparison with Other Prognostic Factors (181) MM Pinto, Y Choi Bridgeport Hospital, Bridgeport, CT; Yale University School of Medicine, New Haven, CT 6 Clinical and Immunohistochemical Associations with Androgen Receptor Expression in Breast Cancer, with an Emphasis on Estrogen Receptor Negative Tumors (78) SN Agoff, PE Swanson, SE Hawes, TJ Lawton University of Washington Medical Center; University of Washington, Seattle, WA 7 Assessment of Actin-Binding Protein Fascin Expression in Stage I and II Invasive Breast Cancer. A Significant Correlation with Aggressive Clinical Behavior (123) V Goncharuk, B Arun, L Middleton, A Sahin UT M.D. Anderson Cancer Center, Houston, TX 8 Survivin Expression in Breast Cancer: Correlation with Proliferation, Angiogenesis, and Prognosis (103) K Coleman, D Sexton, G Cotsonis, C Cohen Emory University, Atlanta, GA 9 Expression of Survivin, Bax and Caspase Proteins in Breast Carcinoma and Correlation with Clinical Outcomes (220) JJ Xiong, P Mecca, PL Depowski, CE Sheehan, AB Boguniewixz, JS Ross Albany Medical College, Albany, NY; St. Joseph's Hospital, Syracuse, NY 10 The Impact of Chromosome X Polysomy in the Progression of Invasive Breast Cancer (211) I Tsirmpa, EG Panayotopoulou, IA Giannopoulou, S Katsarou, NP Givalos, A Keramopoulos, LL Nakopoulou Medical School, the National and Kapodistrian University of Athens, Athens, Greece; "Alexandra" Hospital, Medical School, University of Athens, Athens, Greece 11 EZH2 Is Over-Expressed during Breast Cancer Progression and Is a Strong Predictor of Poor Outcome in Patients with ER-Negative Breast Cancer (151) CG Kleer, R Shen, AM Chinnaiyan, MA Rubin University of Michigan, Ann Arbor, MI; Brigham and Women Hospital, Boston, MA 12 Application of Microarray for Analysis of Tumor Chracteristics; Usefullness and Limitation (215) S Umemura Y Sekido, N Kumaki, H Itoh, Y Tokuda, T Tajima, M Shirane, K Mori, RY Osamura Tokai University School of Medicine, Isehara, Kanagawa, Japan; Nippon Roche Research Center, Kamakura, Kangawa, Japan 13 Identificaton and Validation of Elevated IGFBP5 Gene Expression in Breast Cancer Metastases by cDNA Microarray and Tissue Microarray (132) X Hao, B Sun, L Hu, HM Wang, C Wu, Y Feng, H Wang, GN Fuller, W Zhang Tianjin Medical University Cancer Hospital, Tianjin, China; The University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Texas Medical School-Houston, Houston, TX 14 Neuroendocrine Marker Expression in Breast Carcinoma: A Tissue Microarray Study (163) N Makretsov, A Coldman, M Cheang, D Huntsman, B Gilks University of British Columbia and Vancouver General Hospital, Vancouver, BC, Canada; British Columbia Cancer Agensy, Vancouver, BC, Canada 15 Tissue Microarray Analysis of Cytokeratins 17 and 5/6 Expression in Breast Cancer Confirms Association with Poor Outcome (140) K Jensen, M Cheang, TO Nielsen, D Hunstman, J Ragaz, B Gilks, M van de Rijn Stanford University, Stanford, CA; British Columbia Cancer Agency, Vancouver, BC, Canada 16 Use of Tissue MIDI-Arrays for HER2 Quality Assurance: A College of American Pathologists Feasibility Study (213) R Tubbs, R Nagle, E Hammond, R DeLellis, E Hsi, M Linden, A Ormsby, N Pettigrew, R Rickert, J Said, I Bayer-Garner, P Roche, G Habegger-Vance, A Brothman, D Persons, K Wilson, J Mascarello, K Rao, ME Herrmann, L Cooley, G Dewald, J Park College of American Pathologists, Chicago, IL 17 Pathological and Clinical Predictors for Response to Neoadjuvant Chemotherapy in Breast Cancer (162) G MacGrogan, C Pallud, J Simonie-Lafontaine, C Sagan, V Verrielle, M Antoine, F Ettore, I Treilleux, P Tas, JP Bellocq, A Ulusakarya Institut Bergonie; Centre Huguenin; Centre Val D'Aurelle; CHU Nantes; Centre Papin; CHU Paris Tenon; Centre Lacassagne; Centre Berard; Laboratoire Les Longs Champs; CHU Strasbourg; Bristol-Myers Squibb, France 18 Prognostic and Predictive Value of Proliferation Markers to Pathological Response of T2-T4N0N1 Breast Carcinomas Treated with Anthracycline-Based Preoperative Chemotherapy (216) A Vincent-Salomon, A Rousseau, M Jouve, P Beuzeboc, B Sigal-Zafrani, P Freneaux, P Genin, C Rosty, K Clough, P Vielh, J Klijanienko, A Alghuzlan, X Sastre-Garau Institut Curie, Paris, France 19 MIB1 and Chemoresponse in Breast Carcinoma (199) S Sharma, MH Saboorian, BB Haley, EP Frenkel, WH Frawley, R Ashfaq University of Texas Southwestern Medical Center at Dallas, TX 20 Characterization of Platelet Derived Growth Factor Receptor (PDGFR) Expression in Breast Cancer Identifies Inflammatory Breast Cancer as a Potential Target for Treatment with PDGFR Inhibitors (153) CG Kleer, R Shen, J Wolf, MA Rubin University of Michigan, Ann Arbor, MI; Brigham and Women Hospital, Boston, MA